Introduction
============

Liver cancer was the second leading cause of cancer-associated mortality worldwide in 2015 ([@b1-ol-0-0-11538]). Patients with HCC have no noticeable symptoms, making an accurate diagnosis challenging; therefore, effective and efficient treatment of HCC should be available at a much earlier stage, and novel biomarkers are required to improve earlier diagnosis of HCC and guide clinical management ([@b2-ol-0-0-11538],[@b3-ol-0-0-11538]).

HCC is associated with increased expression levels of α-fetoprotein (AFP) ([@b4-ol-0-0-11538]). AFP is a serum glycoprotein that has been widely used as a conventional biomarker for HCC ([@b5-ol-0-0-11538]). However, the expression levels of AFP remain normal in \>30% of patients with HCC at the time of diagnosis. In addition, relatively low AFP expression levels have been identified in approximately 30% of HCC ([@b5-ol-0-0-11538]). Although AFP is often used in combination with ultrasound for an accurate diagnosis of HCC, novel biomarkers may improve the diagnostic accuracy and detection rates ([@b6-ol-0-0-11538],[@b7-ol-0-0-11538]).

Guanine nucleotide-binding protein subunit α (GNA) is a member of the guanine nucleotide-binding (G protein) family that serve as modulators or transducers in miscellaneous transmembrane signaling systems ([@b8-ol-0-0-11538],[@b9-ol-0-0-11538]). Mutations in G protein subunits α14 (GNA14), αQ (GNAQ) and α11, are involved in \~50% of cherry hemangiomas and cherry-like hemangiomas, and pathological and molecular studies have demonstrated common functions of GNA14 mutations in vascular neoplasms ([@b10-ol-0-0-11538]). In addition, GNA14 silencing has been demonstrated to impair the proliferation of endometrial carcinoma cells by enhancing apoptosis and inducing cell cycle arrest ([@b11-ol-0-0-11538]). Additionally, somatic activating mutations in GNA14 induce the activation of the MAPK signaling pathway and contribute to the occurrence and development of congenital and sporadic vascular tumors, providing novel insight into the underlying mechanisms of carcinogenesis ([@b12-ol-0-0-11538]).

The present study investigated the prognostic value of GNA14 expression levels in HCC according using data from The Cancer Genome Atlas (TCGA). Additionally, biological processes and signaling pathways associated with GNA14 that may be involved in the molecular pathogenesis of HCC were identified based on the Gene Set Enrichment Analysis (GSEA) analysis. Overall, the present study aimed to explore the role of GNA14 in HCC.

Materials and methods
=====================

### Data sources

RNA-sequencing (RNA-seq) data (workflow type, htseq-counts) and matching clinical data of 377 patients were obtained from the Genomic Data Commons data portal (<https://portal.gdc.cancer.gov/>) in June 2019, including information from TCGA database and the Therapeutically Applicable Research to Generate Effective Treatments program. The clinicopathological characteristics included age, sex, histological grade, clinical stage, T, N and M staging ([@b13-ol-0-0-11538]). According to a previous study ([@b14-ol-0-0-11538]), the processing of data and further analysis were conducted to explore the associations between GNA14 expression levels and clinicopathological characteristics in HCC. An unpaired t-test was performed to analyze the difference between tumor and normal samples.

### Integrative Molecular Database of Hepatocellular Carcinoma (HCCDB) analysis

The HCCDB ([http://lifeome.net/database/hccdb/) (15](http://lifeome.net/database/hccdb/) (15)) is an integrated molecular database of HCC with 15 HCC gene expression datasets including 3,917 samples. The HCCDB includes 13 datasets from the Gene Expression Omnibus database and 2 RNA-seq datasets from TCGA liver hepatocellular carcinoma (LIHC) and the International Cancer Genome Consortium (ICGC) databases to explore the expression levels of GNA14 mRNA in HCC.

### Oncomine database analysis

Oncomine is a cancer microarray database ([oncomine.org/](oncomine.org/)) containing 715 datasets and 86,733 cancer samples ([@b16-ol-0-0-11538]). In the present study, Oncomine was used to further assess the expression levels of GNA14 in HCC and adjacent normal tissue. The parameters were set as fold-change ≥2 and P\<0.05, and the top 10% of ranked genes were exhibited.

### DNA methylation level of GNA14

The DNA methylation levels of GNA14 were analyzed using the Methylation in Human Cancer database (MethHC) ([methhc.mbc.nctu.edu.tw/](methhc.mbc.nctu.edu.tw/)) ([@b17-ol-0-0-11538]), a comprehensive database of DNA methylation and gene expression in human cancer. Unpaired t-tests were performed to analyze the difference between tumor and normal samples.

### Tumor Immune Estimation Resource (TIMER) database analysis

A systematic assessment of the correlation between different immune cells, such as B cells, CD4^+^ T cells, CD8^+^ T cells, neutrophils, macrophages, and dendritic cells, and GNA14 expression levels across different types of cancer were performed using the TIMER database ([https://cistrome.shinyapps.io/timer/) (18](https://cistrome.shinyapps.io/timer/) (18)).

### GSEA

Gene set enrichment analysis (GSEA) was conducted using c2.cp.kegg.v6.0.symbols.gmt as a reference gene set ([software.broadinstitute.org/gsea](software.broadinstitute.org/gsea)/) ([@b19-ol-0-0-11538]). A list of genes was obtained from GSEA to account for the survival differences in patients with differential expression levels of GNA14. Gene set permutations were analyzed 1,000 times. In addition, the normalized enrichment score, normalized P-value and false discovery rate (FDR) q value were applied to filter the correlative pathways.

### Statistical analysis

Statistical analysis was performed using R software version 3.6.0 ([http://www.R-project.org/) (20](http://www.R-project.org/) (20)), R studio software version 1.2.5019 ([@b21-ol-0-0-11538]) and GraphPad Prism version 8.0 software (GraphPad Software, Inc.) for data processing and analysis. All data were represented as mean ± standard deviation (SD). According to the median value of GNA14 expression levels in HCC tissues, patients were divided into low and high GNA14 expression groups. Survival analysis was conducted by the Kaplan-Meier method. Wilcoxon signed-rank test and log regression were used to analyze the association of clinicopathological characteristics and GNA14 expression levels. The univariate and multivariate Cox proportional hazards model was performed to evaluate the prognostic value of GNA14 expression. Receiver operating characteristic (ROC) curves were constructed using log-rank tests to evaluate the diagnostic value of GNA14 expression in HCC. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Patient characteristics

Clinical and RNA-seq data of 377 patients with primary HCC, including 377 HCC and 50 adjacent normal tissues, were obtained from TCGA database and are listed in [Table I](#tI-ol-0-0-11538){ref-type="table"}. Of the 377 patients, 122 (32.4%) were female and 255 (67.6%) were male, with a median age of 61 years at diagnosis, ranging between 16 and 81 years. The distribution of conventional histological grades G1--4 was 15.4, 49.0, 32.4 and 3.2%, respectively. In addition, division of the patients based on clinical stage resulted in 125 (51.9%) patients with stage I, 60 (24.9%) patients with stage II, 55 (22.8%) patients with stage III and one (0.4%) patient with stage IV disease. There were 128 (50.4%) patients with T1 stage, 65 (25.6%) with T2 stage disease, 54 (21.3%) with T3 stage disease and 7 (2.8%) with T4 stage disease. Moreover, only one (0.4%) patient had confirmed N1 status, 177 (69.7%) with N0 status and others (29.9%) with Nx status. Additionally, one patient (0.4%) had confirmed M1 status, 186 (72.9%) with N0 status and others (26.7%) with Nx status.

### Differential expression of GNA14 in HCC

As presented in [Fig. 1A](#f1-ol-0-0-11538){ref-type="fig"}, GNA14 expression levels were evaluated in multiple types of the tumor using the TIMER database. GNA14 expression levels were significantly decreased in bladder urothelial carcinoma, breast invasive carcinoma, cholangiocarcinoma, colon adenocarcinoma, esophageal carcinoma, head and neck squamous cell carcinoma, kidney chromophobe, kidney renal clear cell carcinoma, kidney renal papillary cell carcinoma, LIHC and other types of cancer. The downregulation of GNA14 expression levels in HCC tissues was further verified using HCCDB and Oncomine ([Fig. 1B and C](#f1-ol-0-0-11538){ref-type="fig"}). Therefore, the differential expression of GNA12 was observed in liver cancer tissues compared with normal liver tissues using multiple databases.

### Association between GNA14 expression levels and clinicopathological characteristics

RNA-seq data and clinical information of 377 patients with HCC from TCGA were used to analyze the association between GNA14 expression levels and patient clinicopathological characteristics. Based on TCGA-LIHC data using an unpaired t-test, the expression of GNA14 was downregulated in HCC tissues compared within the normal tissues (P\<0.001; [Fig. 2A](#f2-ol-0-0-11538){ref-type="fig"}). Moreover, expression of GNA14 in HCC was lower compared with that in adjacent non-cancerous tissue (P\<0.001; [Fig. 2B](#f2-ol-0-0-11538){ref-type="fig"}). In addition, univariate logistic regression revealed that GNA14 expression levels were associated with histological grade \[odds ratio (OR), 0.114; P=0.009), clinical stage (OR, 0.418; P=0.001) and T stage (OR, 0.508; P=0.013) in HCC ([Table II](#tII-ol-0-0-11538){ref-type="table"}). These findings suggested that reduced expression levels of GNA14 were associated with an advanced histological grade, clinical stage and T stage in HCC.

### Survival outcomes and multivariate analysis

According to the median value of GNA14 expression levels in HCC tissues, patients were divided into low and high GNA14 expression groups. Kaplan-Meier survival analysis of data from TCGA-LIHC indicated that low GNA14 expression levels were associated with a less favorable survival rate compared with that of patients with high GNA14 expression (P=0.002; [Fig. 3A](#f3-ol-0-0-11538){ref-type="fig"}). To investigate the characteristics of GNA14 as a potential tumor marker in HCC, ROC curve analysis was performed, and the area under the ROC curve was 0.8840 (P\<0.001; [Fig. 3B](#f3-ol-0-0-11538){ref-type="fig"}), indicating that GNA14 expression levels were a potential tumor marker for the diagnosis of HCC. Additionally, univariate Cox regression analysis indicated that low expression levels of GNA14 were associated with unfavorable survival \[hazard ratio (HR), 0.527; 95% confidence interval (CI), 0.351--0.791; P=0.002, [Table III](#tIII-ol-0-0-11538){ref-type="table"}). Other clinicopathological features such as clinical stage and T stage were also associated with less favorable survival ([Table IIIa](#tIII-ol-0-0-11538){ref-type="table"}). In addition, multivariate Cox regression analysis revealed that low expression levels of GNA14 were associated with unfavorable survival (HR, 0.636; 95% CI, 0.425--0.953; P=0.028; [Table IIIb](#tIII-ol-0-0-11538){ref-type="table"}. These findings indicated that GNA14 expression levels may have potential as a novel predictor for survival in HCC.

### DNA methylation analysis of GNA14 in HCC

The methylation levels across the GNA14 gene regions, including the promoter, TSS1500, TSS200, the 5′ untranslated region (5′UTR), CpG islands and N shores, were assessed in HCC using the MethHC database. As presented in [Fig. 4](#f4-ol-0-0-11538){ref-type="fig"}, the levels of GNA14 DNA methylation were increased in HCC compared with the normal liver tissues in all analyzed regions, such as the promoter, TSS1500, TSS200, the 5′ untranslated region (5′UTR), CpG islands and N shores.

### Association of tumor-infiltrating immune cells (TIICs) with GNA14 expression levels in HCC

As presented in [Fig. 5A](#f5-ol-0-0-11538){ref-type="fig"}, GNA14 expression levels were partially correlated with the number of infiltrating B cells (partial correlation, −0.191; P\<0.001) and macrophages (partial correlation, −0.132; P=0.015) in HCC as determined by the TIMER database. In addition, GNA14 expression levels were partially negatively correlated with catenin beta 1 (CTNNB1; partial correlation, 0.126; P=0.015), ryanodine receptor 2 (RYR2; partial correlation, 0.17; P=0.001), filaggrin (FLG; partial correlation, 0.196; P\<0.001), CUB and Sushi multiple domains 3 (CSMD3; partial correlation, −0.11; P=0.034) and calcium voltage-gated channel subunit alpha1 E (CACNA1E; partial correlation, −0.206; P\<0.001) expression levels in HCC ([Fig. 5B](#f5-ol-0-0-11538){ref-type="fig"}). The results showed that the low expression of GNA14 might be closely related to immunotherapy.

### Pathway enrichment analysis

GSEA was used to identify signaling pathways enriched in high and low GNA14 expression groups. As presented in [Fig. 6](#f6-ol-0-0-11538){ref-type="fig"} and [Table IV](#tIV-ol-0-0-11538){ref-type="table"}, in the low GNA14 expression group, the significantly enriched signaling pathways were 'ribosome', 'DNA replication', 'homologous recombination', 'RNA polymerase' and 'base excision repair'. By contrast, 'complement and coagulation cascades', 'fatty acid metabolism', 'valine, leucine and isoleucine degradation', 'beta-alanine metabolism' and 'tryptophan metabolism' were enriched in the high GNA14 expression group. These results showed that the low expression of GNA14 was closely related to several tumor-related signaling pathways.

Discussion
==========

Recent studies have suggested a potential role for GNA14 in HCC. For example, activating mutations in GNAQ and GNA14 are frequently presented in hepatic small vessel neoplasms ([@b22-ol-0-0-11538]). A recent study on aberrant DNA methylation of differentially expressed genes in HCC has also revealed that GNAQ serves as a hub gene ([@b23-ol-0-0-11538]). Additionally, a previous study revealed that GNA14 exhibited enhanced methylation in HCC compared with adjacent non-cancerous tissue ([@b24-ol-0-0-11538]). To best of our knowledge, the association between GNA14 expression levels and HCC prognosis has not been elucidated to date. In the present study, the role of GNA14 in HCC was investigated using bioinformatics analysis.

A previous study of the GSE6764 gene expression dataset in the Gene Expression Omnibus database revealed that the expression levels of GNA14 were reduced in HCC tissues compared with normal liver tissue ([@b25-ol-0-0-11538]). In addition, a CpG island methylation phenotype-associated prognostic model involved in the expression of PLEKHB1, ESR1, SLCO2A1, and GNA14 was trained and validated in HCC, serving as an independent prognostic factor for HCC ([@b26-ol-0-0-11538]). However, the role of GNA14 expression levels in diagnosis and prognosis of hepatocellular carcinoma is still unclear.

In the present study, the RNA-seq data were analyzed to explore the role of GNA14 in HCC. GNA14 was demonstrated to be downregulated in HCC compared with normal liver tissue, and these results were verified using the HCCDB and Oncomine databases. In the present study, GNA14 expression levels and their potential prognostic value were investigated. It was demonstrated that GNA14 is abnormally expressed in HCC, and the prognostic value of GNA14 in HCC was also investigated. The results showed that the downregulation of GNA14 in HCC was associated with an unfavorable prognosis, indicating that GNA14 might exert a crucial part in HCC. The results of the present study revealed that low GNA14 expression levels were associated with advanced clinicopathological features, including histological grade, clinical stage and T stage, poor survival outcomes and an unfavorable prognosis. To the best of our knowledge, the present study was the first to assess the prognostic value of GNA14 in HCC using bioinformatics analysis. To the best of our knowledge, the present study is the first to provide novel insight into the role of GNA14 expression levels in HCC.

DNA methylation is a major epigenetic modification that regulates gene expression and is crucial for tumor occurrence and development ([@b27-ol-0-0-11538]). In the present study, the methylation levels across the GNA14 gene regions, including the promoter, TSS1500, TSS200, 5′UTR, CpG island regions, and N shores, were assessed in HCC. The results indicated that downregulation of GNA14 was correlated with its hypermethylation in the promoter region and gene body region. Furthermore, the correlation between GNA14 expression levels and the numbers of TIICs was evaluated. Of note, GNA14 expression levels were partially correlated with the infiltration level of B cells and macrophages. Additionally, GNA14 expression levels were partially correlated with CTNNB1, RYR2, FLG, CSMD3 and CACNA1E expression levels in HCC.

GSEA analysis was performed in the present study using TCGA-LIHC data to explore the potential function of GNA14 in HCC. The 'ribosome', 'DNA replication', 'homologous recombination', 'RNA polymerase' and 'base excision repair' pathways were enriched in the low GNA14 expression group. 'Complement and coagulation cascades', 'fatty acid metabolism', 'valine, leucine and isoleucine degradation', 'beta-alanine metabolism' and 'tryptophan metabolism' were enriched in the high GNA14 expression group. These signaling pathways were regulated by GNA14 expression and may be crucial in the carcinogenesis of HCC. The results indicated that GNA14 expression might have potential prognostic value in HCC and might be an underlying biomarker for patients with HCC.

There were certain limitations to the present study. Firstly, the present study lacked experimental validation and functional research is needed to confirm the role of GNA14 in HCC in future research. Secondly, adjuvant chemotherapy may have effects on GNA14 expression and the information on patients who received adjuvant chemotherapy was not obtained. Lastly, cancer-specific survival was not analyzed in the present study. Unlike overall survival, cancer-specific survival excludes death due to causes unrelated to cancer. It would be more appropriate to use different survival terms to describe prognosis in future research.

In conclusion, GNA14 may have the potential to guide the diagnosis and treatment of HCC. Further experimental studies should be explored to verify the biological function of GNA14 in HCC.
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![Differential expressions of GNA14 evaluated using the TIMER, HCCDB and Oncomine databases for HCC. (A) Expression levels of GNA14 evaluated in multiple tumor types using the TIMER database. (B) Differential expression levels of GNA14 evaluated using the HCCDB database. (C) GNA14 expression levels assessed in multiple types of tumors using the Oncomine database. \*P\<0.05, \*\*P\<0.01, \*\*\*P\<0.001. GNA14, guanine nucleotide-binding protein subunit α14; TIMER, Tumor Immune Estimation Resource; HCCDB, Integrative Molecular Database of Hepatocellular Carcinoma; HCC, hepatocellular carcinoma; RSEM, RNA-Seq by Expectation Maximization.](ol-20-01-0165-g00){#f1-ol-0-0-11538}

![GNA14 expression was assessed in HCC tissues compared with normal or paracancerous tissues based on TCGA-LIHC data. (A) GNA14 expression was assessed in HCC tissues compared with normal tissues. (B) GNA14 expression was assessed in HCC tissues compared with 50 pairs of paracancerous tissues. HCC, hepatocellular carcinoma; GNA14, guanine nucleotide-binding protein subunit α14; TCGA, The Cancer Genome Atlas; LIHC, liver hepatocellular carcinoma.](ol-20-01-0165-g01){#f2-ol-0-0-11538}

![Prognostic value of GNA14 expression levels in HCC. (A) Kaplan-Meier survival analysis based on GNA14 expression levels. (B) Potential prognostic value of GNA14 expression in HCC according to the receiver operating characteristic curve analysis. GNA14, guanine nucleotide-binding protein subunit α14; HCC, hepatocellular carcinoma; AUC, area under the curve.](ol-20-01-0165-g02){#f3-ol-0-0-11538}

![Methylation levels of the GNA14 gene in the promoter, TSS1500, TSS200, 5′UTR, CpG islands, N shore regions in hepatocellular carcinoma tissues based on MethHC database analysis. \*\*P\<0.005. GNA14, guanine nucleotide-binding protein subunit α14; UTR, untranslated region.](ol-20-01-0165-g03){#f4-ol-0-0-11538}

![Correlation of GNA14 expression levels with TIICs and high-frequency gene expression in HCC using the TIMER database. (A) Correlation of GNA14 expression levels and TIICs in HCC, including B cells, CD4+ T cells, CD8+ T cells, neutrophils, macrophages, and dendritic cells. (B) The correlation of GNA14 expression and high-frequency gene expression, including CTNNB1, RYR2, CSMD3, CACNA1E, and FLG, using the 'correlation' module of the TIMER database. GNA14, guanine nucleotide-binding protein subunit α14; HCC, hepatocellular carcinoma; CTNNB1, catenin beta 1; RYR2, ryanodine receptor 2; CSMD3, CUB and Sushi multiple domains 3; CACNA1E, calcium voltage-gated channel subunit alpha1 E; FLG, filaggrin; LIHC, liver hepatocellular carcinoma; TIICs, tumor-infiltrating immune cells; RSEM, RNA-Seq by Expectation Maximization.](ol-20-01-0165-g04){#f5-ol-0-0-11538}

![Enrichment plots from gene set enrichment analysis.](ol-20-01-0165-g05){#f6-ol-0-0-11538}

###### 

The clinicopathological characteristics of 377 patients with hepatocellular carcinoma.

  Characteristic                    n             \%
  --------------------------------- ------------- ------
  Age at diagnosis, years (range)   61 (16--81)   
  Sex                                             
    Female                          122           32.4
    Male                            255           67.6
  Grade                                           
    G1                                39          15.4
    G2                              124           49.0
    G3                                82          32.4
    G4                                8           3.2
  Clinical stage                                  
    I                               125           51.9
    II                                60          24.9
    III                               55          22.8
    IV                                1           0.4
  T stage                                         
    T1                              128           50.4
    T2                                65          25.6
    T3                                54          21.3
    T4                                7           2.8
  N stage                                         
    N0                              177           69.7
    N1                                1           0.4
    Nx                                76          29.9
  M stage                                         
    M0                              186           72.9
    M1                                1           0.4
    Mx                                68          26.7

###### 

GNA14 expression and clinicopathological characteristics analyzed using log regression.

  Clinical characteristics    Total   Odds ratio in GNA14 expression   P-value
  --------------------------- ------- -------------------------------- -----------------------------------------------------
  Age, years, continuous      370     1.001 (0.986--1.016)             0.905
  Sex, female vs. male        371     1.237 (0.801--1.915)             0.337
  Grade, G1 vs. G3            177     0.114 (0.016--0.487)             0.009^[a](#tfn1-ol-0-0-11538){ref-type="table-fn"}^
  M, M0 vs. M1                270     1.9×10-7 (NA-3.2×1029)           0.983
  N, N0 vs. N1                256     1.049 (0.124--8.851)             0.962
  Clinical stage, I vs. III   256     0.418 (0.243--0.710)             0.001^[a](#tfn1-ol-0-0-11538){ref-type="table-fn"}^
  T, T1 vs. T3                261     0.508 (0.296--0.864)             0.013

P\<0.05. M, metastasis; N, nodal involvement; T, tumor.

###### 

Association between overall survival and clinicopathological features in patients with hepatocellular carcinoma in The Cancer Genome Atlas Liver Hepatocellular Carcinoma database using Cox regression and Multivariate Cox regression analysis.

  A, Cox regression analysis                                            
  --------------------------------------------- -------- -------------- -------------------------------------------------------
  Age, years, continuous                        1.011    0.996--1.026   0.154
  Sex, female vs. male                          0.814    0.552--1.200   0.298
  Grade, G1 vs. G4                              1.113    0.862--1.438   0.412
  Clinical stage, I vs. IV                      1.669    1.357--2.053   \<0.001^[a](#tfn2-ol-0-0-11538){ref-type="table-fn"}^
  T, T1 vs. T4                                  1.649    1.354--2.009   \<0.001^[a](#tfn2-ol-0-0-11538){ref-type="table-fn"}^
  M, M0 vs. M1                                  1.180    0.950--1.465   0.134
  N, N0 vs. N1                                  1.076    0.863--1.342   0.513
  GNA14 expression                              0.527    0.351--0.791   0.002^[a](#tfn2-ol-0-0-11538){ref-type="table-fn"}^
                                                                        
  **B, Multivariate Cox regression analysis**                           
                                                                        
  **Characteristic**                            **HR**   **95% CI**     **P-value**
                                                                        
  GNA14 expression                              0.636    0.425--0.953   0.028^[a](#tfn2-ol-0-0-11538){ref-type="table-fn"}^

P\<0.05. HR, hazard ratio; CI, confidence interval; GNA14, guanine nucleotide-binding protein subunit α14; T, tumor; M, metastasis; N, nodal involvement.

###### 

Pathways were enriched in guanine nucleotide-binding protein subunit α14 expression differential phenotype.

  Gene set name                                NES      NOM P-value   FDR q-value
  -------------------------------------------- -------- ------------- -------------
  Complement and coagulation cascades          2.290    \<0.001       \<0.001
  Fatty acid metabolism                        1.939    0.004         0.015
  Valine, leucine and isoleucine degradation   1.855    0.002         0.033
  Beta alanine metabolism                      1.933    \<0.001       0.014
  Tryptophan metabolism                        1.973    0.002         0.012
  Ribosome                                     −1.850   0.002         0.026
  DNA replication                              −1.785   \<0.001       0.044
  Homologous recombination                     −1.888   \<0.001       0.027
  RNA polymerase                               −1.948   \<0.001       0.016
  Base excision repair                         −1.869   \<0.001       0.026

NES, normalized enrichment score; FDR, false discovery rate.

[^1]: Contributed equally
